Mike Garrison to Retire from BD

Mike Garrison to Retire from BD

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.

BD (Becton, Dickinson and Company) Logo

Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD's Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. Prior to joining BD in 2005, Garrison held various roles across R&D and marketing within the MedTech industry.

"Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions," said Tom Polen, Chairman, CEO and President of BD. "He has built strong teams, developed exceptional leaders and helped position our business for the future. We are grateful for Mike's leadership, partnership and many contributions to BD, and we wish him well in his retirement."

Garrison will remain in his role through the end of the fiscal year. A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Polen, streamlining the operating model and reflecting the segment's strategic importance as a growth driver.

"It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world," Garrison said. "I will always value the people, purpose and impact that have made my time at BD so meaningful, and I look forward to seeing the company continue to advance the future of care."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

Contacts:


Media

Investors

Megan Dubrowski
Senior Director, Executive Communications
Megan.Dubrowski@bd.com 

Shawn Bevec

SVP, Investor Relations

Investor_Relations@bd.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mike-garrison-to-retire-from-bd-302831520.html

SOURCE BD (Becton, Dickinson and Company)

News Provided by PR Newswire via QuoteMedia

BDX
The Conversation (0)
Red Mountain Mining

Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter

Red Mountain Mining Limited (ASX: RMX, US CODE: RMXFF, or “Company”), a Critical Minerals exploration and development company with an established portfolio in Tier-1 Mining Districts in the United States and Australia, is pleased to announce the Company’s newly-acquired Thompson Falls Antimony... Keep Reading...
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus™. This first-in-class blood test is available from Thursday, 27 March... Keep Reading...
Bcal Diagnostics Limited

BCAL Commences US Operations

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”) is pleased to announce that it has established a North Carolina, United States of America, incorporated wholly owned subsidiary, BCAL Diagnostics, Inc. (“BCAL US”) which will commence operations on 2 September 2024.... Keep Reading...
TSXV:SYH

Skyharbour Signs Option Agreement with Black Shield Metals Corp to Option 75% of the Mann Lake Uranium Project

Skyharbour Resources Ltd. (TSX-V: SYH ) (OTCQB: SYHBF ) (Frankfurt: SC1P ) ("Skyharbour" or the "Company") is pleased to announce that it has entered into an option agreement (the "Option Agreement") with Black Shield Metals Corp. (CSE: BDX) ("Black Shield") which provides Black Shield an... Keep Reading...
vegn stock cse

CSE Reports April 2021 Market Statistics

CSE is increasingly the exchange of choice for successful entrepreneursThe Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of April 2021. Trading volume exceeded three billion shares, while the total capital raised by issuers exceeded $1... Keep Reading...

Interactive Chart

Latest Press Releases

Related News